Analyst consensus rating
Cogent Biosciences Analyst Rating: Strong Buy
Direct answer
Cogent Biosciences's consensus rating is Strong Buy.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $55.73.
Forecast evidence checked November 12, 2026.
Get free Cogent Biosciences email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $29.40
- Average price target
- $55.73
- High price target
- $61.00
- Low price target
- $45.00
- Low target gap
- +53.1%
- Target upside
- +89.5%
- High target gap
- +107.5%
- Target range width
- 54.4%
- Consensus rating
- Strong Buy
- Analysts
- 11
- Evidence date
- November 12, 2026
- Valid through
- November 19, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Cogent Biosciences?
Cogent Biosciences has a verified Strong Buy consensus. The same dataset has an average price target of $55.73.
How far are Cogent Biosciences's low and high targets from the recorded price?
The low target implies +53.1%, while the high target implies +107.5%.
How many analysts are included in Cogent Biosciences's consensus?
The verified consensus includes 11 analysts.
How is Cogent Biosciences's target upside or downside calculated?
The average target of $55.73 is divided by the recorded price of $29.40, then one is subtracted to produce +89.5%. This does not guarantee a future return.
When was Cogent Biosciences's analyst forecast verified?
The data was verified on 2026-11-12. The dataset is valid through 2026-11-19.